rs914458 — PTPN1 PTPN1 downstream variant

PTP1B — The Molecular Brake on Insulin and Leptin Signaling

Protein tyrosine phosphatase 1B¹¹ Protein tyrosine phosphatase 1B
PTP1B: an enzyme that removes phosphate groups from tyrosine residues, turning off activated signaling proteins. It is encoded by PTPN1 on chromosome 20q13 (PTP1B) is one of the most intensively studied drug targets in metabolic medicine. It acts as a molecular brake on two critical hormonal pathways: insulin signaling (which controls blood glucose) and leptin signaling (which controls appetite and body weight). When PTP1B is overactive, the body becomes less sensitive to both hormones — a state that promotes elevated blood sugar and weight gain.

rs914458 sits approximately 10 kilobases downstream of the PTPN1 gene's 3' end, in a region now annotated within the neighboring RIPOR3 locus but historically described as a PTPN1 downstream regulatory variant. It does not alter any protein's amino acid sequence but tags a regulatory region that may influence PTPN1 expression or the chromatin environment surrounding the gene.

The Mechanism

PTP1B directly dephosphorylates the insulin receptor²² dephosphorylates the insulin receptor
Dephosphorylation: removal of a phosphate group that was added during receptor activation; this turns the receptor "off" and terminates the signaling cascade. PTP1B therefore shortens the duration of each insulin signal and its substrate IRS-1, attenuating downstream glucose uptake. In the hypothalamus, it dephosphorylates JAK2 — the kinase activated immediately after leptin binds its receptor — blunting the leptin signal that normally suppresses appetite and increases energy expenditure.

Knockout mice lacking PTP1B³³ Knockout mice lacking PTP1B
Zabolotny JM et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell, 2002 are hypersensitive to both insulin and leptin, maintain leanness on high-fat diets, and show enhanced hypothalamic signaling in response to leptin administration. Brain-specific PTP1B deletion recapitulates the whole-body phenotype⁴⁴ recapitulates the whole-body phenotype
Cho H. Protein tyrosine phosphatase 1B (PTP1B) and obesity. Vitam Horm, 2013, establishing that the neuronal pool of PTP1B is the dominant driver of metabolic regulation — not the peripheral enzyme in liver or muscle.

How rs914458 influences PTP1B expression has not been mechanistically characterized. The variant is in an intergenic/downstream region and may act through a long-range regulatory element, or it may be in linkage disequilibrium⁵⁵ linkage disequilibrium
Linkage disequilibrium (LD): the tendency for nearby genetic variants to be inherited together. A downstream marker can "tag" a functional variant elsewhere without itself being causal with a functional variant elsewhere in the PTPN1 locus.

The Evidence

The primary association comes from a French population study⁶⁶ French population study
Cheyssac C et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Med Genet, 2006 examining 14 PTPN1-region SNPs across a T2D case-control sample. Among all 14 variants, rs914458 showed the strongest diabetes association: OR 1.43 [95% CI 1.06–1.94] under a dominant model (p = 0.02). The same variant was also associated with moderate obesity: OR 1.20 1.01–1.43⁷⁷ 1.01–1.43. The C allele was the risk allele in both analyses.

However, a larger replication study⁸⁸ replication study
Florez JC et al. Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people. Diabetes, 2005 in 7,883 participants (3,347 T2D cases, 3,347 controls) found no significant association between PTPN1 tag-SNPs and T2D despite >95% power to detect the reported effect sizes. This non-replication means rs914458 is currently supported by a single population study and should be treated as an emerging rather than established risk marker.

The biological plausibility of the PTPN1 locus remains strong — PTP1B inhibition is actively pursued in drug development, with trodusquemine (a natural PTP1B inhibitor) reaching Phase 2 clinical trials for obesity and metabolic disease.

Practical Actions

For carriers of the risk-associated C allele — CG and CC genotypes — the actionable implication centers on dietary strategies that reduce the demand on insulin signaling and support leptin sensitivity. Because PTP1B dampens insulin receptor signaling, dietary choices that reduce insulin spike frequency and magnitude are particularly relevant: emphasizing lower glycemic-load meals reduces the cumulative PTP1B activation burden.

Importantly, the evidence for this specific SNP is preliminary. Carriers should not treat it as a confirmed high-risk marker; rather, it is a signal to be aware of the PTP1B pathway and consider lifestyle strategies that support insulin and leptin sensitivity.

Interactions

Two intronic PTPN1 variants — rs941798 and rs2426159 — showed stronger and more consistent associations with metabolic traits in the Cheyssac study, including fasting insulin, HOMA-B, and lipid markers. If a user carries risk alleles at both rs914458 and these intronic variants, the combined signal suggests broader PTPN1 locus involvement in their metabolic risk profile. The TCF7L2 variant rs7903146 (impaired beta-cell insulin secretion) and PPARG rs1801282 (reduced peripheral insulin sensitivity) both converge on insulin signaling through independent mechanisms; co-carriage of these variants with rs914458 risk alleles may amplify overall metabolic vulnerability.